Research graph
References from Noninvasive Assessment of Tumor VEGF Receptors in Response to Treatment with Pazopanib: A Molecular Imaging Study. Local targets link to admitted publications; unresolved targets remain external evidence.
Predicting benefit from antiangiogenic agents in malignancy
10.1038/nrc1946 · 2006 · External reference
Cutting off cancer's supply lines
10.1038/458686b · 2009 · External reference
Antiangiogenic therapy: creating a unique “window” of opportunity
2004 · External reference
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
10.1038/ncponc0403 · 2006 · External reference
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
10.1038/ncponc1150 · 2008 · External reference
VEGF-targeted therapy: mechanisms of antitumour activity
10.1038/nrc2403 · 2008 · External reference
Modes of resistance to antiangiogenic therapy
10.1038/nrc2442 · 2008 · External reference
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia
10.1158/0008-5472.can-05-3295 · 2006 · External reference
Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts
10.1158/1535-7163.mct-07-0142 · 2007 · External reference
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
10.1007/s00280-006-0393-4 · 2007 · External reference
Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment
10.1158/0008-5472.can-08-0285 · 2008 · External reference
Vertical VEGF targeting: a combination of ligand blockade with receptor tyrosine kinase inhibition
10.1016/j.ejca.2008.07.013 · 2008 · External reference
Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis
10.1016/j.bcp.2007.09.029 · 2008 · External reference
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
10.1074/jbc.273.46.30336 · 1998 · External reference
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
10.1172/jci24612 · 2006 · External reference
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
10.1126/science.1127592 · 2006 · External reference
Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy
10.1158/0008-5472.can-07-0905 · 2007 · External reference
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
10.1200/jco.2007.14.5375 · 2008 · External reference
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis
10.1016/j.eururo.2008.10.021 · 2009 · External reference
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
10.1016/j.ccr.2009.01.021 · 2009 · External reference
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
10.1016/j.ccr.2009.01.027 · 2009 · External reference
Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF based probes
10.1038/nm1522 · 2007 · External reference
Direct labeling of Cys-tag in scVEGF with technetium 99m
10.1021/bc7004818 · 2008 · External reference
Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins
10.1007/978-1-59745-419-3_16 · 2008 · External reference
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, amultikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
10.1158/1535-7163.mct-07-0193 · 2007 · External reference
Pazopnib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy
2008 · External reference
Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization
10.1038/sj.onc.1202478 · 1999 · External reference
VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing
10.1016/j.yexcr.2007.02.020 · 2007 · External reference
Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells
10.1111/j.1600-0854.2006.00462.x · 2006 · External reference
Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia
10.2967/jnumed.107.041335 · 2007 · External reference
New approaches for imaging tumour responses to treatment
10.1038/nrc2289 · 2008 · External reference
Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic MRI and PET studies of a preclinical tumor model of tumor hypoxia
10.1593/neo.81360 · 2009 · External reference
A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized 13C-labeled pyruvate utilization as methods for detecting tumor response to treatment
10.1593/neo.09254 · 2009 · External reference
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
10.1016/j.ccr.2005.09.005 · 2005 · External reference
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy
10.1158/1078-0432.ccr-09-0095 · 2009 · External reference
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited
10.1016/j.ccr.2009.02.007 · 2009 · External reference
Resistance to EGF-R (erbB-1) and VEGF-R modulating agents
10.1016/j.ejca.2008.11.038 · 2009 · External reference
The anti-angiogenesis basis of metronomic chemotherapy
10.1038/nrc1369 · 2004 · External reference
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
10.1126/science.1104819 · 2005 · External reference
Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?
10.1007/s00259-008-0813-2 · 2008 · External reference
Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab
10.1074/jbc.m507783200 · 2006 · External reference
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans
10.1067/mcp.2002.126179 · 2002 · External reference
Validation of novel imaging methodologies for use as cancer clinical trial end-points
10.1016/j.ejca.2008.10.030 · 2009 · External reference
